S-1 ORAL ANTICANCER AGENT IMPROVES PATIENTS’ SURVIVAL IN ADJUVANT GASTRIC CANCER TRIAL VERSUS SURGERY ALONE
Contact :sanofi-aventis Taiho PharmaceuticalSalah MAHYAOUI Atsushi AZUMA+ 33 6 73 68 78 88 + 81-3-3294-4524Anne BANCILLON+ 33 1 53 77 47 94S-1 ORAL ANTICANCER AGENT IMPROVES PATIENTS’ SURVIVAL IN ADJUVANT GASTRIC CANCER TRIAL VERSUS SURGERY ALONEOne of the most important advances in early stage gastric cancer in forty yearsParis, France and Tokyo, Japan - January 19, 2007 - Results of the large randomised phase III study (ACTS-GC) announced at the 2007 Gastrointestinal Cancers Symposium in Orlando, USA, showed that the oral anticancer agent S-1 reduced significantly the